Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Neurology
Published in: Journal of Neurology 11/2023

31-07-2023 | Autoimmune Encephalitis | Review

Movement disorders in autoimmune encephalitis: an update

Authors: Mengting Qin, Jiaojiao Chen, Xiaoqing Guo, Xuying Xiang, Lei Nie, Yong Wang, Ling Mao

Published in: Journal of Neurology | Issue 11/2023

Login to get access

Abstract

Autoimmune encephalitis (AE) is a form of encephalitis resulting from an immune response targeting central nervous system antigens, which is characterized by cognitive impairment, neuropsychiatric symptoms, seizures, movement disorders (MDs), and other encephalopathy symptoms. MDs frequently manifest throughout the progression of the disease, with recurrent involuntary movements leading to discomfort and, in some cases, necessitating admission to the intensive care unit. Prompt identification and management of MDs can aid in the diagnosis and prognosis of AE. This review synthesizes current knowledge on the characteristics, underlying mechanisms, and treatment options for MDs in the context of AE.
Literature
1.
Abboud H, Probasco JC, Irani S, Ances B, Benavides DR, Bradshaw M, Christo PP, Dale RC, Fernandez-Fournier M, Flanagan EP, Gadoth A, George P, Grebenciucova E, Jammoul A, Lee ST, Li Y, Matiello M, Morse AM, Rae-Grant A, Rojas G, Rossman I, Schmitt S, Venkatesan A, Vernino S, Pittock SJ, Titulaer MJ (2021) Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management. J Neurol Neurosurg Psychiatry 92:757–768PubMedCrossRef
2.
Dash D, Pandey S (2019) Movement disorders associated with neuronal antibodies. Acta Neurol Scand 139:106–117PubMedCrossRef
3.
Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, Dessain SK, Rosenfeld MR, Balice-Gordon R, Lynch DR (2008) Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 7:1091–1098PubMedPubMedCentralCrossRef
4.
Irani SR, Vincent A (2011) NMDA receptor antibody encephalitis. Curr Neurol Neurosci Rep 11:298–304PubMedCrossRef
5.
Pittock SJ, Yoshikawa H, Ahlskog JE, Tisch SH, Benarroch EE, Kryzer TJ, Lennon VA (2006) Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction. Mayo Clin Proc 81:1207–1214PubMedCrossRef
6.
Xiao XQ, Tang N, Liu C, Wang HX, Jiang Q, Deng YJ, Ding YQ (2011) Construction of a PCR chip for detecting genes associated with metastatic colorectal cancer and its preliminary application. Nan Fang Yi Ke Da Xue Xue Bao 31:1169–1174PubMed
7.
Flanagan EP, Geschwind MD, Lopez-Chiriboga AS, Blackburn KM, Turaga S, Binks S, Zitser J, Gelfand JM, Day GS, Dunham SR, Rodenbeck SJ, Clardy SL, Solomon AJ, Pittock SJ, McKeon A, Dubey D, Zekeridou A, Toledano M, Turner LE, Vernino S, Irani SR (2023) Autoimmune encephalitis misdiagnosis in adults. JAMA Neurol 80:30–39PubMedCrossRef
8.
Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, Cortese I, Dale RC, Gelfand JM, Geschwind M, Glaser CA, Honnorat J, Hoftberger R, Iizuka T, Irani SR, Lancaster E, Leypoldt F, Pruss H, Rae-Grant A, Reindl M, Rosenfeld MR, Rostasy K, Saiz A, Venkatesan A, Vincent A, Wandinger KP, Waters P, Dalmau J (2016) A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 15:391–404PubMedPubMedCentralCrossRef
9.
Seery N, Butzkueven H, O’Brien TJ, Monif M (2022) Contemporary advances in anti-NMDAR antibody (Ab)-mediated encephalitis. Autoimmun Rev 21:103057PubMedCrossRef
10.
Titulaer MJ, McCracken L, Gabilondo I, Armangue T, Glaser C, Iizuka T, Honig LS, Benseler SM, Kawachi I, Martinez-Hernandez E, Aguilar E, Gresa-Arribas N, Ryan-Florance N, Torrents A, Saiz A, Rosenfeld MR, Balice-Gordon R, Graus F, Dalmau J (2013) Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 12:157–165PubMedPubMedCentralCrossRef
11.
Mohammad SS, Fung VS, Grattan-Smith P, Gill D, Pillai S, Ramanathan S, Brilot F, Dale RC (2014) Movement disorders in children with anti-NMDAR encephalitis and other autoimmune encephalopathies. Mov Disord 29:1539–1542PubMedCrossRef
12.
Lin N, Huang Y, Jin L, Lu Q, Liu Q, Zhou X, Guan H (2020) Electroencephalogram and clinical characteristics and correlations in patients with anti-N-methyl-d-aspartate receptor encephalitis. Clin EEG Neurosci 51:51–60PubMedCrossRef
13.
Irani SR, Bera K, Waters P, Zuliani L, Maxwell S, Zandi MS, Friese MA, Galea I, Kullmann DM, Beeson D, Lang B, Bien CG, Vincent A (2010) N-methyl-d-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 133:1655–1667PubMedPubMedCentralCrossRef
14.
Varley JA, Webb AJS, Balint B, Fung VSC, Sethi KD, Tijssen MAJ, Lynch T, Mohammad SS, Britton F, Evans M, Hacohen Y, Lin JP, Nardocci N, Granata T, Dale RC, Lim MJ, Bhatia KP, Lang AE, Irani SR (2019) The Movement disorder associated with NMDAR antibody-encephalitis is complex and characteristic: an expert video-rating study. J Neurol Neurosurg Psychiatry 90:724–726PubMedCrossRef
15.
Florance NR, Davis RL, Lam C, Szperka C, Zhou L, Ahmad S, Campen CJ, Moss H, Peter N, Gleichman AJ, Glaser CA, Lynch DR, Rosenfeld MR, Dalmau J (2009) Anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol 66:11–18PubMedPubMedCentralCrossRef
16.
Ramanathan S, Al-Diwani A, Waters P, Irani SR (2021) The autoantibody-mediated encephalitides: from clinical observations to molecular pathogenesis. J Neurol 268:1689–1707PubMedCrossRef
17.
Duan BC, Weng WC, Lin KL, Wong LC, Li ST, Hsu MH, Lin JJ, Fan PC, Lin MI, Chiu NC, Lin YC, Wang HS, Hung KL, Lee WT (2016) Variations of movement disorders in anti-N-methyl-d-aspartate receptor encephalitis: a nationwide study in Taiwan. Medicine (Baltimore) 95:e4365PubMedCrossRef
18.
Davies G, Irani SR, Coltart C, Ingle G, Amin Y, Taylor C, Radcliffe J, Hirsch NP, Howard RS, Vincent A, Kullmann DM (2010) Anti-N-methyl-d-aspartate receptor antibodies: a potentially treatable cause of encephalitis in the intensive care unit. Crit Care Med 38:679–682PubMedCrossRef
19.
Gresa-Arribas N, Planaguma J, Petit-Pedrol M, Kawachi I, Katada S, Glaser CA, Simabukuro MM, Armangue T, Martinez-Hernandez E, Graus F, Dalmau J (2016) Human neurexin-3alpha antibodies associate with encephalitis and alter synapse development. Neurology 86:2235–2242PubMedPubMedCentralCrossRef
20.
Lumsden DE, Allen NM (2018) Rethinking status dystonicus: a welcome start to a challenging problem. Mov Disord 33:344PubMedCrossRef
21.
Lumsden DE, Lundy C, Fairhurst C, Lin JP (2013) Dystonia Severity Action Plan: a simple grading system for medical severity of status dystonicus and life-threatening dystonia. Dev Med Child Neurol 55:671–672PubMedCrossRef
22.
Zhang Y, Cui L, Chen W, Huang H, Liu G, Su Y, Boltze J (2023) Status dystonicus in adult patients with anti-N-methyl-d-aspartate-acid receptor encephalitis. J Neurol 270:2693–2701PubMedCrossRef
23.
Wang W, Zhang L, Chi XS, He L, Zhou D, Li JM (2019) Psychiatric symptoms of patients with anti-NMDA receptor encephalitis. Front Neurol 10:1330PubMedCrossRef
24.
Warren N, O’Gorman C, McKeon G, Swayne A, Blum S, Siskind D (2021) Psychiatric management of anti-NMDAR encephalitis: a cohort analysis. Psychol Med 51:435–440PubMedCrossRef
25.
26.
Rogers JP, Oldham MA, Fricchione G, Northoff G, Ellen WJ, Mann SC, Francis A, Wieck A, Elizabeth WL, Lewis G, Grover S, Hirjak D, Ahuja N, Zandi MS, Young AH, Fone K, Andrews S, Kessler D, Saifee T, Gee S, Baldwin DS, David AS (2023) Evidence-based consensus guidelines for the management of catatonia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 37:327–369PubMedPubMedCentralCrossRef
27.
Huang Q, Wu Y, Qin R, Wei X, Ma M (2016) Clinical characteristics and outcomes between children and adults with anti-N-Methyl-d-Aspartate receptor encephalitis. J Neurol 263:2446–2455PubMedCrossRef
28.
Lizcano-Meneses A, Watanabe N, von Glehn F, Barbosa R, de Albuquerque M, Yassuda C, Moraes AS, Martinez JW, Santos LMB, Cendes F (2021) Clinical variables that help in predicting the presence of autoantibodies in patients with acute encephalitis. Seizure 90:117–122PubMedCrossRef
29.
Seery N, Butzkueven H, O’Brien TJ, Monif M (2022) Contemporary advances in antibody-mediated encephalitis: anti-LGI1 and anti-Caspr2 antibody (Ab)-mediated encephalitides. Autoimmun Rev 21:103074PubMedCrossRef
30.
Irani SR, Michell AW, Lang B, Pettingill P, Waters P, Johnson MR, Schott JM, Armstrong RJ, Alessandro SZ, Bleasel A, Somerville ER, Smith SM, Vincent A (2011) Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol 69:892–900PubMedCrossRef
31.
Lai M, Huijbers MG, Lancaster E, Graus F, Bataller L, Balice-Gordon R, Cowell JK, Dalmau J (2010) Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 9:776–785PubMedPubMedCentralCrossRef
32.
Tofaris GK, Irani SR, Cheeran BJ, Baker IW, Cader ZM, Vincent A (2012) Immunotherapy-responsive chorea as the presenting feature of LGI1-antibody encephalitis. Neurology 79:195–196PubMedPubMedCentralCrossRef
33.
Gadoth A, Pittock SJ, Dubey D, McKeon A, Britton JW, Schmeling JE, Smith A, Kotsenas AL, Watson RE, Lachance DH, Flanagan EP, Lennon VA, Klein CJ (2017) Expanded phenotypes and outcomes among 256 LGI1/CASPR2-IgG-positive patients. Ann Neurol 82:79–92PubMedCrossRef
34.
Kurtis MM, Toledano R, Garcia-Morales I, Gil-Nagel A (2015) Immunomodulated parkinsonism as a presenting symptom of LGI1 antibody encephalitis. Parkinsonism Relat Disord 21:1286–1287PubMedCrossRef
35.
36.
D’Orsi G, Martino T, Lalla A, Claudio MTD, Carapelle E, Avolio C (2018) Faciobrachial dystonic seizures expressed as epileptic spasms, followed by focal seizures in anti-LGI1 encephalitis: a video-polygraphic study. Epileptic Disord 20:525–529PubMedCrossRef
37.
Beimer NJ, Selwa LM (2017) Seizure semiology of anti-LGI1 antibody encephalitis. Epileptic Disord 19:461–464PubMedCrossRef
38.
Fantaneanu TA, Bhattacharyya S, Milligan TA, Pennell PB (2016) Rapidly cycling auras and episodic focal dystonia in anti-LGI1 autoimmune encephalitis. JAMA Neurol 73:1150PubMedCrossRef
39.
Navarro V, Kas A, Apartis E, Chami L, Rogemond V, Levy P, Psimaras D, Habert MO, Baulac M, Delattre JY, Honnorat J (2016) Motor cortex and hippocampus are the two main cortical targets in LGI1-antibody encephalitis. Brain 139:1079–1093PubMedCrossRef
40.
Irani SR, Stagg CJ, Schott JM, Rosenthal CR, Schneider SA, Pettingill P, Pettingill R, Waters P, Thomas A, Voets NL, Cardoso MJ, Cash DM, Manning EN, Lang B, Smith SJ, Vincent A, Johnson MR (2013) Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain 136:3151–3162PubMedCrossRef
41.
Binks SNM, Klein CJ, Waters P, Pittock SJ, Irani SR (2018) LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes. J Neurol Neurosurg Psychiatry 89:526–534PubMedCrossRef
42.
Thompson J, Bi M, Murchison AG, Makuch M, Bien CG, Chu K, Farooque P, Gelfand JM, Geschwind MD, Hirsch LJ, Somerville E, Lang B, Vincent A, Leite MI, Waters P, Irani SR (2018) The importance of early immunotherapy in patients with faciobrachial dystonic seizures. Brain 141:348–356PubMedCrossRef
43.
Flanagan EP, Kotsenas AL, Britton JW, McKeon A, Watson RE, Klein CJ, Boeve BF, Lowe V, Ahlskog JE, Shin C, Boes CJ, Crum BA, Laughlin RS, Pittock SJ (2015) Basal ganglia T1 hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures. Neurol Neuroimmunol Neuroinflamm 2:e161PubMedPubMedCentralCrossRef
44.
Mo J, Dong W, Cui T, Chen C, Shi W, Hu W, Zhang C, Wang X, Zhang K, Shao X (2022) Whole-brain metabolic pattern analysis in patients with anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis. Eur J Neurol 29:2376–2385PubMedCrossRef
45.
Irani SR, Alexander S, Waters P, Kleopa KA, Pettingill P, Zuliani L, Peles E, Buckley C, Lang B, Vincent A (2010) Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia. Brain 133:2734–2748PubMedPubMedCentralCrossRef
46.
Joubert B, Gobert F, Thomas L, Saint-Martin M, Desestret V, Convers P, Rogemond V, Picard G, Ducray F, Psimaras D, Antoine JC, Delattre JY, Honnorat J (2017) Autoimmune episodic ataxia in patients with anti-CASPR2 antibody-associated encephalitis. Neurol Neuroimmunol Neuroinflamm 4:e371PubMedPubMedCentralCrossRef
47.
Joubert B, Saint-Martin M, Noraz N, Picard G, Rogemond V, Ducray F, Desestret V, Psimaras D, Delattre JY, Antoine JC, Honnorat J (2016) Characterization of a subtype of autoimmune encephalitis with anti-contactin-associated protein-like 2 antibodies in the cerebrospinal fluid, prominent limbic symptoms, and seizures. JAMA Neurol 73:1115–1124PubMedCrossRef
48.
Govert F, Abrante L, Becktepe J, Balint B, Ganos C, Hofstadt-van OU, Krogias C, Varley J, Irani SR, Paneva S, Titulaer MJ, de Vries JM, Boon AJW, Schreurs MWJ, Joubert B, Honnorat J, Vogrig A, Arino H, Sabater L, Dalmau J, Scotton S, Jacob S, Melzer N, Bien CG, Geis C, Lewerenz J, Pruss H, Wandinger KP, Deuschl G, Leypoldt F (2023) Distinct movement disorders in contactin-associated-protein-like-2 antibody-associated autoimmune encephalitis. Brain 146:657–667PubMedCrossRef
49.
Balint B, Regula JU, Jarius S, Wildemann B (2013) Caspr2 antibodies in limbic encephalitis with cerebellar ataxia, dyskinesias and myoclonus. J Neurol Sci 327:73–74PubMedCrossRef
50.
van Sonderen A, Arino H, Petit-Pedrol M, Leypoldt F, Kortvelyessy P, Wandinger KP, Lancaster E, Wirtz PW, Schreurs MW, Sillevis SPA, Graus F, Dalmau J, Titulaer MJ (2016) The clinical spectrum of Caspr2 antibody-associated disease. Neurology 87:521–528PubMedPubMedCentralCrossRef
51.
Lancaster E, Lai M, Peng X, Hughes E, Constantinescu R, Raizer J, Friedman D, Skeen MB, Grisold W, Kimura A, Ohta K, Iizuka T, Guzman M, Graus F, Moss SJ, Balice-Gordon R, Dalmau J (2010) Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol 9:67–76PubMedCrossRef
52.
van Coevorden-Hameete MH, de Bruijn M, de Graaff E, Bastiaansen D, Schreurs MWJ, Demmers JAA, Ramberger M, Hulsenboom ESP, Nagtzaam MMP, Boukhrissi S, Veldink JH, Verschuuren J, Hoogenraad CC, Sillevis SPAE, Titulaer MJ (2019) The expanded clinical spectrum of anti-GABABR encephalitis and added value of KCTD16 autoantibodies. Brain 142:1631–1643PubMedPubMedCentralCrossRef
53.
Deng B, Cai M, Qiu Y, Liu X, Yu H, Zhang X, Huang H, Zhao X, Yang W, Dong S, Jin L, Chu S, Chen X (2022) MRI characteristics of autoimmune encephalitis with autoantibodies to GABAA receptor: a case series. Neurol Neuroimmunol Neuroinflamm 9:e1158PubMedPubMedCentralCrossRef
54.
Hoftberger R, Titulaer MJ, Sabater L, Dome B, Rozsas A, Hegedus B, Hoda MA, Laszlo V, Ankersmit HJ, Harms L, Boyero S, de Felipe A, Saiz A, Dalmau J, Graus F (2013) Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients. Neurology 81:1500–1506PubMedPubMedCentralCrossRef
55.
Spatola M, Petit-Pedrol M, Simabukuro MM, Armangue T, Castro FJ, Barcelo AMI, Julia BMR, Benson L, Gorman M, Felipe A, Caparo ORL, Rosenfeld MR, Graus F, Dalmau J (2017) Investigations in GABA(A) receptor antibody-associated encephalitis. Neurology 88:1012–1020PubMedPubMedCentralCrossRef
56.
Malter MP, Helmstaedter C, Urbach H, Vincent A, Bien CG (2010) Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol 67:470–478PubMedCrossRef
57.
Zhu F, Shan W, Lv R, Li Z, Wang Q (2020) Clinical characteristics of GAD 65-associated autoimmune encephalitis. Acta Neurol Scand 142:281–293PubMedCrossRef
58.
Budhram A, Sechi E, Flanagan EP, Dubey D, Zekeridou A, Shah SS, Gadoth A, Naddaf E, McKeon A, Pittock SJ, Zalewski NL (2021) Clinical spectrum of high-titre GAD65 antibodies. J Neurol Neurosurg Psychiatry 92:645–654PubMedCrossRef
59.
Dalakas MC (2022) Stiff-person syndrome and GAD antibody-spectrum disorders: GABAergic neuronal excitability, immunopathogenesis and update on antibody therapies. Neurotherapeutics 19:832–847PubMedPubMedCentralCrossRef
60.
Pierrot-Deseilligny C, Milea D (2005) Vertical nystagmus: clinical facts and hypotheses. Brain 128:1237–1246PubMedCrossRef
61.
62.
Hoftberger R, van Sonderen A, Leypoldt F, Houghton D, Geschwind M, Gelfand J, Paredes M, Sabater L, Saiz A, Titulaer MJ, Graus F, Dalmau J (2015) Encephalitis and AMPA receptor antibodies: novel findings in a case series of 22 patients. Neurology 84:2403–2412PubMedPubMedCentralCrossRef
63.
Boronat A, Gelfand JM, Gresa-Arribas N, Jeong HY, Walsh M, Roberts K, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R, Graus F, Rudy B, Dalmau J (2013) Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels. Ann Neurol 73:120–128PubMedCrossRef
64.
Tobin WO, Lennon VA, Komorowski L, Probst C, Clardy SL, Aksamit AJ, Appendino JP, Lucchinetti CF, Matsumoto JY, Pittock SJ, Sandroni P, Tippmann-Peikert M, Wirrell EC, McKeon A (2014) DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients. Neurology 83:1797–1803PubMedPubMedCentralCrossRef
65.
Hara M, Arino H, Petit-Pedrol M, Sabater L, Titulaer MJ, Martinez-Hernandez E, Schreurs MW, Rosenfeld MR, Graus F, Dalmau J (2017) DPPX antibody-associated encephalitis: main syndrome and antibody effects. Neurology 88:1340–1348PubMedPubMedCentralCrossRef
66.
Gaig C, Graus F, Compta Y, Hogl B, Bataller L, Bruggemann N, Giordana C, Heidbreder A, Kotschet K, Lewerenz J, Macher S, Marti MJ, Montojo T, Perez-Perez J, Puertas I, Seitz C, Simabukuro M, Tellez N, Wandinger KP, Iranzo A, Ercilla G, Sabater L, Santamaria J, Dalmau J (2017) Clinical manifestations of the anti-IgLON5 disease. Neurology 88:1736–1743PubMedPubMedCentralCrossRef
67.
Sabater L, Planaguma J, Dalmau J, Graus F (2016) Cellular investigations with human antibodies associated with the anti-IgLON5 syndrome. J Neuroinflamm 13:226CrossRef
68.
69.
Dale RC, Merheb V, Pillai S, Wang D, Cantrill L, Murphy TK, Ben-Pazi H, Varadkar S, Aumann TD, Horne MK, Church AJ, Fath T, Brilot F (2012) Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders. Brain 135:3453–3468PubMedCrossRef
70.
Kalampokini S, Motkova I, Bargiotas P, Artemiadis A, Zis P, Hadjigeorgiou GM (2023) A case of unusual presentation with anti-glycine receptor (GlyR) and myelin oligodentrocyte glycoprotein (MOG) antibody. Clin Park Relat Disord 8:100195PubMedPubMedCentral
71.
Ren M, Zhou Q (2023) Stroke-like presentation of autoimmune chorea with positive anti-Yo and anti-MOG antibodies: a case report. Neurol Sci 44:347–349PubMedCrossRef
72.
Hou C, Wu W, Tian Y, Zhang Y, Zhu H, Zeng Y, Peng B, Zheng K, Li X, Chen W (2020) Clinical analysis of anti-NMDAR encephalitis combined with MOG antibody in children. Mult Scler Relat Disord 42:102018PubMedCrossRef
73.
Sturchio A, Dwivedi AK, Gastaldi M, Grimberg MB, Businaro P, Duque KR, Vizcarra JA, Abdelghany E, Balint B, Marsili L, Espay AJ (2022) Movement disorders associated with neuronal antibodies: a data-driven approach. J Neurol 269:3511–3521PubMedPubMedCentralCrossRef
74.
Giannoccaro MP, Wright SK, Vincent A (2019) In vivo mechanisms of antibody-mediated neurological disorders: animal models and potential implications. Front Neurol 10:1394PubMedCrossRef
75.
Pan H, Oliveira B, Saher G, Dere E, Tapken D, Mitjans M, Seidel J, Wesolowski J, Wakhloo D, Klein-Schmidt C, Ronnenberg A, Schwabe K, Trippe R, Matz-Rensing K, Berghoff S, Al-Krinawe Y, Martens H, Begemann M, Stocker W, Kaup FJ, Mischke R, Boretius S, Nave KA, Krauss JK, Hollmann M, Luhder F, Ehrenreich H (2019) Uncoupling the widespread occurrence of anti-NMDAR1 autoantibodies from neuropsychiatric disease in a novel autoimmune model. Mol Psychiatry 24:1489–1501PubMedCrossRef
76.
77.
Ding Y, Zhou Z, Chen J, Peng Y, Wang H, Qiu W, Xie W, Zhang J, Wang H (2021) Anti-NMDAR encephalitis induced in mice by active immunization with a peptide from the amino-terminal domain of the GluN1 subunit. J Neuroinflamm 18:53CrossRef
78.
Linnoila J, Pulli B, Armangue T, Planaguma J, Narsimhan R, Schob S, Zeller MWG, Dalmau J, Chen J (2019) Mouse model of anti-NMDA receptor post-herpes simplex encephalitis. Neurol Neuroimmunol Neuroinflamm 6:e529PubMedCrossRef
79.
Stamelou M, Plazzi G, Lugaresi E, Edwards MJ, Bhatia KP (2012) The distinct movement disorder in anti-NMDA receptor encephalitis may be related to status dissociatus: a hypothesis. Mov Disord 27:1360–1363PubMedCrossRef
80.
Mahowald MW, Schenck CH (1991) Status dissociates—a perspective on states of being. Sleep 14:69–79PubMedCrossRef
81.
Kleinig TJ, Thompson PD, Matar W, Duggins A, Kimber TE, Morris JG, Kneebone CS, Blumbergs PC (2008) The distinctive movement disorder of ovarian teratoma-associated encephalitis. Mov Disord 23:1256–1261PubMedCrossRef
82.
Tassinari CA, Rubboli G, Gardella E, Cantalupo G, Calandra-Buonaura G, Vedovello M, Alessandria M, Gandini G, Cinotti S, Zamponi N, Meletti S (2005) Central pattern generators for a common semiology in fronto-limbic seizures and in parasomnias. A neuroethologic approach. Neurol Sci 26(Suppl 3):s225–s232PubMedCrossRef
83.
Lalic T, Pettingill P, Vincent A, Capogna M (2011) Human limbic encephalitis serum enhances hippocampal mossy fiber-CA3 pyramidal cell synaptic transmission. Epilepsia 52:121–131PubMedCrossRef
84.
Petit-Pedrol M, Sell J, Planaguma J, Mannara F, Radosevic M, Haselmann H, Ceanga M, Sabater L, Spatola M, Soto D, Gasull X, Dalmau J, Geis C (2018) LGI1 antibodies alter Kv1.1 and AMPA receptors changing synaptic excitability, plasticity and memory. Brain 141:3144–3159PubMedPubMedCentral
85.
Kornau HC, Kreye J, Stumpf A, Fukata Y, Parthier D, Sammons RP, Imbrosci B, Kurpjuweit S, Kowski AB, Fukata M, Pruss H, Schmitz D (2020) Human cerebrospinal fluid monoclonal lgi1 autoantibodies increase neuronal excitability. Ann Neurol 87:405–418PubMedCrossRef
86.
Fels E, Mayeur ME, Wayere E, Vincent C, Malleval C, Honnorat J, Pascual O (2022) Dysregulation of the hippocampal neuronal network by LGI1 auto-antibodies. PLoS ONE 17:e0272277PubMedPubMedCentralCrossRef
87.
88.
Seagar M, Russier M, Caillard O, Maulet Y, Fronzaroli-Molinieres L, De San FM, Boumedine-Guignon N, Rodriguez L, Zbili M, Usseglio F, Formisano-Treziny C, Youssouf F, Sangiardi M, Boillot M, Baulac S, Benitez MJ, Garrido JJ, Debanne D, El FO (2017) LGI1 tunes intrinsic excitability by regulating the density of axonal Kv1 channels. Proc Natl Acad Sci USA 114:7719–7724PubMedPubMedCentralCrossRef
89.
Irani SR, Buckley C, Vincent A, Cockerell OC, Rudge P, Johnson MR, Smith S (2008) Immunotherapy-responsive seizure-like episodes with potassium channel antibodies. Neurology 71:1647–1648PubMedCrossRef
90.
Wang Y, Yu Y, Hu Y, Li Y, Song F, Wang Y (2020) Clinical and electroencephalographic features of the seizures in neuronal surface antibody-associated autoimmune encephalitis. Front Neurol 11:280PubMedPubMedCentralCrossRef
91.
Striano P (2011) Faciobrachial dystonic attacks: seizures or movement disorder? Ann Neurol 70:179–180 (author reply 180)PubMedCrossRef
92.
Boesebeck F, Schwarz O, Dohmen B, Graef U, Vestring T, Kramme C, Bien CG (2013) Faciobrachial dystonic seizures arise from cortico-subcortical abnormal brain areas. J Neurol 260:1684–1686PubMedCrossRef
93.
Kaaden T, Madlener M, Angstwurm K, Bien CG, Bogarin Y, Doppler K, Finke A, Gerner ST, Reimann G, Hausler M, Handreka R, Hellwig K, Kaufmann M, Kellinghaus C, Koertvelyessy P, Kraft A, Lewerenz J, Menge T, Paliantonis A, von Podewils F, Pruss H, Rauer S, Ringelstein M, Rostasy K, Schirotzek I, Schwabe J, Sokolowski P, Suesse M, Suhs KW, Surges R, Tauber SC, Thaler F, Bergh FT, Urbanek C, Wandinger KP, Wildemann B, Mues S, Zettl U, Leypoldt F, Melzer N, Geis C, Malter M, Kunze A (2022) Seizure semiology in antibody-associated autoimmune encephalitis. Neurol Neuroimmunol Neuroinflamm 9:e200034PubMedPubMedCentralCrossRef
94.
Iyer RS, Ramakrishnan TCR, Karunakaran SA, Kamaleshwaran KK (2017) Faciobrachial dystonic seizures result from fronto-temporo-basalganglial network involvement. Epilepsy Behav Case Rep 8:47–50PubMedPubMedCentralCrossRef
95.
Li TR, Zhang YD, Wang Q, Shao XQ, Lv RJ (2021) Recognition of seizure semiology and semiquantitative FDG-PET analysis of anti-LGI1 encephalitis. CNS Neurosci Ther 27:1173–1181PubMedPubMedCentralCrossRef
96.
Mizobuchi M, Matsuda K, Inoue Y, Sako K, Sumi Y, Chitoku S, Tsumaki K, Takahashi M (2004) Dystonic posturing associated with putaminal hyperperfusion depicted on subtraction SPECT. Epilepsia 45:948–953PubMedCrossRef
97.
98.
Romoli M, Krashia P, Sen A, Franciotta D, Gastaldi M, Nobili A, Mancini A, Nardi CE, Nigro P, Tambasco N, Mercuri NB, Parnetti L, Di Filippo M, D’Amelio M, Irani SR, Costa C, Calabresi P (2019) Hippocampal epileptogenesis in autoimmune encephalitis. Ann Clin Transl Neurol 6:2261–2269PubMedPubMedCentralCrossRef
99.
Joubert B, Petit-Pedrol M, Planaguma J, Mannara F, Radosevic M, Marsal M, Maudes E, Garcia-Serra A, Aguilar E, Andres-Bilbe A, Gasull X, Loza-Alvarez P, Sabater L, Rosenfeld MR, Dalmau J (2022) Human CASPR2 antibodies reversibly alter memory and the CASPR2 protein complex. Ann Neurol 91:801–813PubMedCrossRef
100.
Benarroch EE (2012) GABAB receptors: structure, functions, and clinical implications. Neurology 78:578–584PubMedCrossRef
101.
102.
Nibber A, Mann EO, Pettingill P, Waters P, Irani SR, Kullmann DM, Vincent A, Lang B (2017) Pathogenic potential of antibodies to the GABA(B) receptor. Epilepsia Open 2:355–359PubMedPubMedCentralCrossRef
103.
Jain Ankit, Lancaster Eric, Dalmau Josep, Balice-Gordon Rita J, Philadelphia PA, Cambridge MA, Barcelona, (2015) Autoantibodies in the CSF of anti-GABABReceptor encephalitis patients block activation of GABAB receptors in vitro. Ann Neurol 78:S77–S77. https://​doi.​org/​10.​1002/​ana.​24498CrossRef
104.
Kreye J, Wright SK, van Casteren A, Stoffler L, Machule ML, Reincke SM, Nikolaus M, van Hoof S, Sanchez-Sendin E, Homeyer MA, Cordero GC, Kornau HC, Schmitz D, Kaindl AM, Boehm-Sturm P, Mueller S, Wilson MA, Upadhya MA, Dhangar DR, Greenhill S, Woodhall G, Turko P, Vida I, Garner CC, Wickel J, Geis C, Fukata Y, Fukata M, Pruss H (2021) Encephalitis patient-derived monoclonal GABAA receptor antibodies cause epileptic seizures. J Exp Med 218:e20210012PubMedPubMedCentral
105.
Brandle SM, Cerina M, Weber S, Held K, Menke AF, Alcala C, Gebert D, Herrmann AM, Pellkofer H, Gerdes LA, Bittner S, Leypoldt F, Teegen B, Komorowski L, Kumpfel T, Hohlfeld R, Meuth SG, Casanova B, Melzer N, Beltran E, Dornmair K (2021) Cross-reactivity of a pathogenic autoantibody to a tumor antigen in GABA(A) receptor encephalitis. Proc Natl Acad Sci USA 118:e1916337118PubMedPubMedCentralCrossRef
106.
Menke AF, Ismail FS, Dornmair K, Cerina M, Meuth SG, Melzer N (2022) GABA(A) receptor autoantibodies decrease GABAergic synaptic transmission in the hippocampal CA3 network. Int J Mol Sci 23:3707PubMedPubMedCentralCrossRef
107.
Seery N, Butzkueven H, O’Brien TJ, Monif M (2022) Rare antibody-mediated and seronegative autoimmune encephalitis: an update. Autoimmun Rev 21:103118PubMedCrossRef
108.
Ali F, Wijdicks EF (2020) Treatment of movement disorder emergencies in autoimmune encephalitis in the neurosciences ICU. Neurocrit Care 32:286–294PubMedCrossRef
109.
Rodriguez A, Klein CJ, Sechi E, Alden E, Basso MR, Pudumjee S, Pittock SJ, McKeon A, Britton JW, Lopez-Chiriboga AS, Zekeridou A, Zalewski NL, Boeve BF, Day GS, Gadoth A, Burkholder D, Toledano M, Dubey D, Flanagan EP (2022) LGI1 antibody encephalitis: acute treatment comparisons and outcome. J Neurol Neurosurg Psychiatry 93:309–315PubMedCrossRef
110.
Kingston S, Mao L, Yang L, Arora A, Fibuch EE, Wang JQ (2006) Propofol inhibits phosphorylation of N-methyl-d-aspartate receptor NR1 subunits in neurons. Anesthesiology 104:763–769PubMedCrossRef
111.
Coluzzi F, Angelini A, Simmaco M, Alampi D, Alessandri E, Grassi E, Monina MG, Rocco M (2020) The effect of dexmedetomidine on status epilepticus in a patient with anti-NMDA receptor encephalitis. Can J Anaesth 67:1677–1679PubMedCrossRef
112.
Yeh MS, Chen GY, Lin CH, Lin CY (2021) A combination of midazolam and dexmedetomidine for anesthesia management in a patient with anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis: a case report. J Clin Anesth 75:110509PubMedCrossRef
113.
Pryzbylkowski PG, Dunkman WJ, Liu R, Chen L (2011) Case report: anti-N-methyl-d-aspartate receptor encephalitis and its anesthetic implications. Anesth Analg 113:1188–1191PubMedPubMedCentralCrossRef
114.
Ding L, Tan H, Li Z, Ji J, Song X (2017) Case report: anaesthetic management of radical gastrectomy for gastric cancer associated with anti-N-methyl-d-aspartate receptor encephalitis. BMC Anesthesiol 17:90PubMedPubMedCentralCrossRef
115.
Lapebie FX, Kennel C, Magy L, Projetti F, Honnorat J, Pichon N, Vignon P, Francois B (2014) Potential side effect of propofol and sevoflurane for anesthesia of anti-NMDA-R encephalitis. BMC Anesthesiol 14:5PubMedPubMedCentralCrossRef
116.
Al GF, Uffman JC, Kim SS, Nafiu OO, Tobias JD (2020) Anesthetic care for patients with anti-NMDA receptor encephalitis. Saudi J Anaesth 14:164–168CrossRef
117.
Yamanaka D, Kawano T, Tateiwa H, Iwata H, Locatelli FM, Yokoyama M (2016) Successful management of dexmedetomidine for postoperative intensive care sedation in a patient with anti-NMDA receptor encephalitis: a case report and animal experiment. Springerplus 5:1380PubMedPubMedCentralCrossRef
118.
Hwang YH, Shon Y, Yoon YJ, Yeom JH (2022) Anesthesia for ovarian teratoma resection using remimazolam and remifentanil in a patient with anti-N-methyl-d-aspartate receptor encephalitis—two case reports. Korean J Anesthesiol 75:530–535PubMedPubMedCentral
119.
Bledsoe IO, Viser AC, San LM (2020) Treatment of dystonia: medications, neurotoxins, neuromodulation, and rehabilitation. Neurotherapeutics 17:1622–1644PubMedPubMedCentralCrossRef
120.
Deffains M, Bergman H (2015) Striatal cholinergic interneurons and cortico-striatal synaptic plasticity in health and disease. Mov Disord 30:1014–1025PubMedCrossRef
121.
Truong DD, Sandroni P, van den Noort S, Matsumoto RR (1995) Diphenhydramine is effective in the treatment of idiopathic dystonia. Arch Neurol 52:405–407PubMedCrossRef
122.
Greene P, Shale H, Fahn S (1988) Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs. Mov Disord 3:46–60PubMedCrossRef
123.
Walker RH, Danisi FO, Swope DM, Goodman RR, Germano IM, Brin MF (2000) Intrathecal baclofen for dystonia: benefits and complications during six years of experience. Mov Disord 15:1242–1247PubMedCrossRef
124.
Albright AL (2006) Intraventricular baclofen infusion for dystonia. Report of two cases. J Neurosurg 105:71–74PubMed
125.
Zheng F, Ye X, Shi X, Poonit ND, Lin Z (2018) Management of refractory orofacial dyskinesia caused by anti-N-methyl-d-aspartate receptor encephalitis using botulinum toxin. Front Neurol 9:81PubMedPubMedCentralCrossRef
126.
127.
Baizabal-Carvallo JF, Stocco A, Muscal E, Jankovic J (2013) The spectrum of movement disorders in children with anti-NMDA receptor encephalitis. Mov Disord 28:543–547PubMedCrossRef
128.
Yushvayev-Cavalier Y, Nichter C, Ramirez-Zamora A (2015) Possible autoimmune association between herpes simplex virus infection and subsequent anti-N-methyl-d-aspartate receptor encephalitis: a pediatric patient with abnormal movements. Pediatr Neurol 52:454–456PubMedCrossRef
129.
Cantarin-Extremera V, Duat-Rodriguez A, Gonzalez-Gutierrez-Solana L, Lopez-Marin L, Armangue T (2013) Clinical case of anti-N-methyl-d-aspartate receptor encephalitis in an 8-month-old patient with hyperkinetic movement disorder. Pediatr Neurol 48:400–402PubMedCrossRef
130.
Bonuccelli U, Ceravolo R, Maremmani C, Nuti A, Rossi G, Muratorio A (1994) Clozapine in Huntington’s chorea. Neurology 44:821–823PubMedCrossRef
131.
132.
133.
Mohammad SS, Jones H, Hong M, Nosadini M, Sharpe C, Pillai SC, Brilot F, Dale RC (2016) Symptomatic treatment of children with anti-NMDAR encephalitis. Dev Med Child Neurol 58:376–384PubMedCrossRef
134.
Iorio R, Damato V, Evoli A, Gessi M, Gaudino S, Di Lazzaro V, Spagni G, Sluijs JA, Hol EM (2018) Clinical and immunological characteristics of the spectrum of GFAP autoimmunity: a case series of 22 patients. J Neurol Neurosurg Psychiatry 89:138–146PubMedCrossRef
135.
Fang B, McKeon A, Hinson SR, Kryzer TJ, Pittock SJ, Aksamit AJ, Lennon VA (2016) Autoimmune glial fibrillary acidic protein astrocytopathy: a novel meningoencephalomyelitis. JAMA Neurol 73:1297–1307PubMedCrossRef
136.
Baizabal-Carvallo JF, Stocco A, Muscal E, Jankovic J (2013) The spectrum of movement disorders in children with anti-NMDA receptor encephalitis. Mov Disord 28:543–547PubMedCrossRef
137.
Pittock SJ, Yoshikawa H, Ahlskog JE, Tisch SH, Benarroch EE, Kryzer TJ, Lennon VA (2006) Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction. Mayo Clin Proc 81:1207–1214PubMedCrossRef
138.
Spatola M, Sabater L, Planaguma J, Martinez-Hernandez E, Armangue T, Pruss H, Iizuka T, Caparo Oblitas RL, Antoine JC, Li R, Heaney N, Tubridy N, Munteis Olivas E, Rosenfeld MR, Graus F, Dalmau J (2018) Encephalitis with mGluR5 antibodies: symptoms and antibody effects. Neurology 90:e1964–e1972PubMedPubMedCentralCrossRef
139.
Rogers JP, Oldham MA, Fricchione G, Northoff G, Ellen WJ, Mann SC, Francis A, Wieck A, Elizabeth WL, Lewis G, Grover S, Hirjak D, Ahuja N, Zandi MS, Young AH, Fone K, Andrews S, Kessler D, Saifee T, Gee S, Baldwin DS, David AS (2023) Evidence-based consensus guidelines for the management of catatonia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 37:327–369PubMedPubMedCentralCrossRef
140.
Damato V, Balint B, Kienzler AK, Irani SR (2018) The clinical features, underlying immunology, and treatment of autoantibody-mediated movement disorders. Mov Disord 33:1376–1389PubMedPubMedCentralCrossRef
Metadata
Title
Movement disorders in autoimmune encephalitis: an update
Authors
Mengting Qin
Jiaojiao Chen
Xiaoqing Guo
Xuying Xiang
Lei Nie
Yong Wang
Ling Mao
Publication date
31-07-2023
Publisher
Springer Berlin Heidelberg
Published in
Journal of Neurology / Issue 11/2023
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-023-11881-1

Other articles of this Issue 11/2023

Journal of Neurology 11/2023 Go to the issue

Original Communication

Evaluation of myotonometry for myotonia, muscle stiffness and elasticity in neuromuscular disorders

Letter to the Editors

Treating progressive multifocal leukoencephalopathy in MS

Original Communication

Associations of Alzheimer's-related plasma biomarkers with cognitive decline in Parkinson's disease

Original Communication

Cortical thickness and cognition in older people with multiple sclerosis

Original Communication

Multiple sclerosis lesions that impair memory map to a connected memory circuit

Letter to the Editors

Menière’s disease with migraine, Menière’s disease without migraine and Vestibular migraine: clinical differences
Image Credits